Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pfizer Inc. is conducting an open-label Phase 1 study titled AN OPEN-LABEL PHASE 1 STUDY TO EVALUATE PF-08046037 AS MONOTHERAPY AND PART OF COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED MALIGNANCIES. The study aims to assess the safety and effects of PF-08046037 alone or combined with sasanlimab in patients with advanced or metastatic cancers, including non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and pancreatic ductal adenocarcinoma. This research is significant as it explores potential new treatments for these challenging conditions.
The interventions being tested are PF-08046037, administered intravenously, and sasanlimab, given subcutaneously. These drugs are intended to treat advanced malignancies by potentially improving patient outcomes.
The study follows a non-randomized, sequential intervention model with no masking, focusing on treatment. It involves dose escalation, optimization, and expansion phases to determine the optimal dosing strategy for both monotherapy and combination therapy.
The study began on May 6, 2025, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
This clinical trial update could influence Pfizer’s stock performance and investor sentiment, as successful outcomes may enhance Pfizer’s oncology portfolio. Investors should also consider the competitive landscape, as advancements in cancer treatment are highly sought after in the pharmaceutical industry.
The study is currently recruiting, with further details available on the ClinicalTrials portal.